Header Logo

Connection

TAO WU to Pyridines

Back to Details
This is a "connection" page, showing publications TAO WU has written about Pyridines.
TAO WU
Connection Strength
0.202
Pyridines
  1. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024 Nov; 212:114328.
    View in: PubMed
    Score: 0.202
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.